- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03033290
Traditional Chinese Medicine on Gut Microbiota and Allergic Diseases
January 24, 2018 updated by: YANG SIEN-HUNG, Chang Gung Memorial Hospital
Effect of Traditional Chinese Medicine on Gut Microbiota, Physical Constitution, and Allergic Diseases
Allergic rhinitis is an importance disease in Taiwan with its high incidence about 20-30% and gradually increased annually.
However, symptom relapse still bothered the majority of patients though there were certain advances in western medicine.
In addition, side effects of western medicine, such as lethargy, mouth dryness were noted.
Traditional Chinese medicine, especially qi-tonifying regimen has been used and proved benefit to the allergic diseases by many researchers.This study will provide the evidences of gut microbiota changes and immune-modulatory effects of BZYQT for the treatment of allergic rhinitis.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Recently studies reported that gut microbiota is related to the human immunity modulation of allergic diseases.
Investigators are interested to know weather qi-tonifying herbal medicine is through the changes of gut microbiota to modulate human immunity.
In this study, a double-blinded, randomized, placebo control design is applied and total 60 perennial allergic rhinitis patients will be enrolled in our study.
All subjects will be divided into Bu-Zhong-Yi-Qi-Tang (BZYQT) and placebo control groups, 40 and 20 subjects each.
Subjects of BZYQT group will receive capsule of BZYQT, 4gm tid, 12gm a day, while control group will receive similar placebo capsule with same scheme.
Total 2 months treatment course will be done.
Gut microbiota will be assayed before and after 2 months treatment.
Additionally, various parameters for immunologic response will be checked before and after the treatment, including the total IgE amount, the ratio of CD4/CD8 of T lymphocytes, the profile of cytokine such as IL-10 and IL-12 as well as functional change of dendritic cells and T cells.
Results will be analyzed statistically including gender analysis.
This study will provide the evidences of gut microbiota changes and immune-modulatory effects of BZYQT for the treatment of allergic rhinitis.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sien-hung Yang, Ph.D.
- Phone Number: 2611 +886-3-3196200
- Email: dryang@ms1.hinet.net
Study Contact Backup
- Name: Yi-Hsuan Lin, M.D.
- Phone Number: 2611 +886-3-3196200
- Email: cynthiajobo@gmail.com
Study Locations
-
-
-
Taoyuan, Taiwan
- Recruiting
- Chang Gung Memorial Hospital
-
Contact:
- Yi-Hsuan Lin, M.D.
- Phone Number: 2611 +886-3-3196200
- Email: cynthiajobo@gmail.com
-
Principal Investigator:
- Sien-hung Yang, Ph.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- With at least one of the following clinical symptoms: itchy nose, sneeze, rhinorrhea, nasal congestion
- Diagnosed as intermittent allergic rhinitis (Less than 4 days per week and for less than 4 weeks)
- CAP panel :allergy to mite
- Will to complete questionnaires and take medicine as schedule in this study
- Volunteer for study enrollment and sign inform consent
Exclusion Criteria:
- Under treatment of western medicine including steroid, antihistamine, leukotriene inhibitor, immunosuppressant or stop above medication less than one month
- Under acute inflammatory disease such as pneumonia, sinusitis, bronchitis and so on
- vasomotor type allergic rhinitis
- history of allergy or adverse effect to Chinese herbs, poor compliance of herbal medicine
- severe organ function impairment, such as heart failure, liver failure, renal failure (eGFR <60 mL/min/1.73 m2)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bu-Zhong-Yi-Qi-Tang (BZYQT)
capsule of BZYQT, 4gm tid, 12gm a day for 2 months
|
Qi-tonifying regimen of traditional Chinese herbal medicine
|
Placebo Comparator: placebo control
similar placebo capsule 4gm tid, 12gm a day for 2 months
|
placebo control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in allergic rhinitis symptom severity
Time Frame: Assessment of symptom severity on Day 0 and 2 months after completing treatment
|
Sino-nasal Outcome Test (SNOT-22)
|
Assessment of symptom severity on Day 0 and 2 months after completing treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of fatigue
Time Frame: Assessment of fatigue severity on Day 0 and 2 months after completing treatment
|
Fatigue Severity Scale
|
Assessment of fatigue severity on Day 0 and 2 months after completing treatment
|
Improvement of life quality
Time Frame: Assessment of life quality on Day 0 and 2 months after completing treatment
|
SF-36
|
Assessment of life quality on Day 0 and 2 months after completing treatment
|
Detection of gut microbiota
Time Frame: Assessment of gut microbiota on Day 0 and 2 months after completing treatment
|
use cecal stool DNA purification and quantification of cecal microbiota by quantitative PCR (qPCR).
Using V3-V5 16S rRNA amplification; Processing of NGS data; Operational Taxonomic Units (OTUs) cluster; Taxonomic profiling
|
Assessment of gut microbiota on Day 0 and 2 months after completing treatment
|
Change in serum total and mite specific IgE
Time Frame: Assessment of serologic markers on Day 0 and 2 months after completing treatment
|
check serum total IgE and mite specific IgE (KIU/l)
|
Assessment of serologic markers on Day 0 and 2 months after completing treatment
|
T Cells measurement
Time Frame: Assessment of CD4/CD8 on Day 0 and 2 months after completing treatment
|
check CD4 / CD8 by flowcytometry
|
Assessment of CD4/CD8 on Day 0 and 2 months after completing treatment
|
Measurement of cytokines produced by polymorphonuclear leukocytes
Time Frame: Assessment of serologic markers on Day 0 and 2 months after completing treatment
|
check sICAM-1,IL-8,PGE2, LTC4
|
Assessment of serologic markers on Day 0 and 2 months after completing treatment
|
Measurement of cytokines produced by monocytes and lymphocytes
Time Frame: Assessment of serologic markers on Day 0 and 2 months after completing treatment
|
IL-4、IL-5、IL-10、IL-13、IFN-γ
|
Assessment of serologic markers on Day 0 and 2 months after completing treatment
|
Detection of dendritic cell function
Time Frame: Assessment of serologic markers on Day 0 and 2 months after completing treatment
|
check IL-10 and IL-12 level
|
Assessment of serologic markers on Day 0 and 2 months after completing treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sien-hung Yang, Ph.D., Chang Gung Memorial Hospital, Taoyuan, Taiwan
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Yang SH, Hong CY, Yu CL. Decreased serum IgE level, decreased IFN-gamma and IL-5 but increased IL-10 production, and suppressed cyclooxygenase 2 mRNA expression in patients with perennial allergic rhinitis after treatment with a new mixed formula of Chinese herbs. Int Immunopharmacol. 2001 Jun;1(6):1173-82. doi: 10.1016/s1567-5769(01)00051-0.
- Yang SH, Hong CY, Yu CL. The stimulatory effects of nasal discharge from patients with perennial allergic rhinitis on normal human neutrophils are normalized after treatment with a new mixed formula of Chinese herbs. Int Immunopharmacol. 2002 Nov;2(12):1627-39. doi: 10.1016/s1567-5769(02)00133-9.
- Yang SH, Yu CL, Chen YL, Chiao SL, Chen ML. Traditional Chinese medicine, Xin-yi-san, reduces nasal symptoms of patients with perennial allergic rhinitis by its diverse immunomodulatory effects. Int Immunopharmacol. 2010 Aug;10(8):951-8. doi: 10.1016/j.intimp.2010.05.008. Epub 2010 May 28.
- Hwang BF, Jaakkola JJ, Lee YL, Lin YC, Guo YL. Relation between air pollution and allergic rhinitis in Taiwanese schoolchildren. Respir Res. 2006 Feb 9;7(1):23. doi: 10.1186/1465-9921-7-23.
- Kuroiwa A, Liou S, Yan H, Eshita A, Naitoh S, Nagayama A. Effect of a traditional Japanese herbal medicine, hochu-ekki-to (Bu-Zhong-Yi-Qi Tang), on immunity in elderly persons. Int Immunopharmacol. 2004 Feb;4(2):317-24. doi: 10.1016/j.intimp.2003.12.004.
- Yang SH, Kao TI, Chiang BL, Chen HY, Chen KH, Chen JL. Immune-modulatory effects of bu-zhong-yi-qi-tang in ovalbumin-induced murine model of allergic asthma. PLoS One. 2015 Jun 2;10(6):e0127636. doi: 10.1371/journal.pone.0127636. eCollection 2015.
- Xie MQ, Liu J, Long Z, Tian DF, Zhao CQ, Yang PC. Modulation of immune tolerance with a Chinese traditional prescription inhibits allergic rhinitis in mice. N Am J Med Sci. 2011 Nov;3(11):503-7. doi: 10.4297/najms.2011.3503.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 10, 2018
Primary Completion (Anticipated)
July 31, 2020
Study Completion (Anticipated)
July 31, 2020
Study Registration Dates
First Submitted
May 31, 2016
First Submitted That Met QC Criteria
January 24, 2017
First Posted (Estimate)
January 26, 2017
Study Record Updates
Last Update Posted (Actual)
January 26, 2018
Last Update Submitted That Met QC Criteria
January 24, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CORPG1F0011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinitis
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AVRecruitingPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis | Local Allergic RhinitisBelgium
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
ALK-Abelló A/SCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Humanis Saglık Anonim SirketiCompletedPerennial Allergic Rhinitis | Seasonal Allergic RhinitisIndia
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
West Penn Allegheny Health SystemPennsylvania Allergy and Asthma Research FoundationCompletedAllergy | Perennial Allergic Rhinitis | Seasonal Allergic RhinitisUnited States
-
Ahn-Gook Pharmaceuticals Co.,LtdSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaboratorsCompletedAllergic Rhinitis | Perennial Allergic Rhinitis | Non-seasonal Allergic RhinitisKorea, Republic of
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
Clinical Trials on Bu-Zhong-Yi-Qi-Tang
-
Chang Gung Memorial HospitalCommittee on Chinese Medicine and PharmacyCompletedAllergic RhinitisTaiwan
-
Hadassah Medical OrganizationTerminatedChildhood Chronic Immune ThrombocytopeniaIsrael
-
Chang Gung Memorial HospitalUnknownCarcinoma, Non-Small-Cell LungTaiwan
-
China Medical University HospitalUnknown
-
China Medical University HospitalCompletedHead and Neck Neoplasm | ChemoradiotherapyTaiwan
-
Chang Gung Memorial HospitalCompleted
-
Chung Shan Medical UniversityCompleted
-
KK Women's and Children's HospitalRecruitingInfertility | Male Infertility | Reproductive Issues | Traditional Chinese Medication (TCM)Singapore
-
Shanghai University of Traditional Chinese MedicineUnknown
-
Guang'anmen Hospital of China Academy of Chinese...China Academy of Chinese Medical SciencesActive, not recruitingIgA Nephropathy at High Risk of Developing ESRDChina